Suppr超能文献

曲马多使用与癫痫发作之间的关联:一项全国性病例-病例-时间对照研究。

Association between tramadol use and seizures: A nationwide case-case-time-control study.

作者信息

Park Sohee, Lee Hyesung, Kim Ju Hwan, Jeon Ha-Lim, Shin Ju-Young

机构信息

School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.

Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Republic of Korea.

出版信息

Pharmacoepidemiol Drug Saf. 2022 Jun;31(6):614-622. doi: 10.1002/pds.5417. Epub 2022 Feb 17.

Abstract

PURPOSE

Tramadol may lower the seizure threshold; however, there is no conclusive evidence to confirm this. This study aimed to determine whether the use of tramadol is associated with the occurrence of seizures.

METHODS

We conducted a case-case-time-control (CCTC) study by identifying patients who had received tramadol and seizure diagnosis in a nationwide healthcare database in South Korea between 2003 and 2015. Each case was matched for age and sex to one future case to adjust for time trends in exposure without selection bias from the use of an external control group. The use of tramadol was assessed during a risk period of 1-30 days, and two reference periods, 61-90 days and 91-120 days, preceding the first diagnosis of seizures. We calculated the adjusted odds ratio (aOR) by dividing the OR in cases (case-crossover) by the OR in future cases (control-crossover). We performed a dose-response analysis using the average daily dose.

RESULTS

We identified 2523 incident cases with matched future cases (mean age, 45.4 years; 50% men). The aOR for seizure with tramadol use was 0.94 (95% confidence interval [CI], 0.98-1.43) in the CCTC analysis, with a case-crossover OR of 1.19 (0.98-1.43) and control-crossover OR of 1.27 (1.03-1.56). The dose-response analysis showed a similar trend in the main analysis: a low-dose aOR of 0.80 (0.50-1.28) and a high-dose aOR of 0.92 (0.41-2.11).

CONCLUSION

We could not identify a significant association between transient use of tramadol and incidence of seizures in clinical practice.

摘要

目的

曲马多可能会降低癫痫发作阈值;然而,尚无确凿证据证实这一点。本研究旨在确定使用曲马多是否与癫痫发作的发生有关。

方法

我们通过在韩国全国医疗数据库中识别2003年至2015年间接受过曲马多治疗且有癫痫诊断的患者,进行了一项病例-病例-时间对照(CCTC)研究。每个病例按年龄和性别与一个未来病例匹配,以调整暴露的时间趋势,避免因使用外部对照组而产生选择偏倚。在癫痫首次诊断前1至30天的风险期以及两个参考期(61至90天和91至120天)评估曲马多的使用情况。我们通过将病例组(病例交叉)的比值比除以未来病例组(对照交叉)的比值比来计算调整后的比值比(aOR)。我们使用平均每日剂量进行剂量反应分析。

结果

我们确定了2523例发病病例及其匹配的未来病例(平均年龄45.4岁;男性占50%)。在CCTC分析中,使用曲马多后癫痫发作的aOR为0.94(95%置信区间[CI],0.98 - 1.43),病例交叉比值比为1.19(0.98 - 1.43),对照交叉比值比为1.27(1.03 - 1.56)。剂量反应分析在主要分析中显示出类似趋势:低剂量aOR为0.80(0.50 - 1.28),高剂量aOR为0.92(0.41 - 2.11)。

结论

在临床实践中,我们未发现短期使用曲马多与癫痫发作发生率之间存在显著关联。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验